MarketCap
Regeneron Pharmaceuticals REGN
Facebook
X
Telegram
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
105 M |
Market Cap[1] |
$ 84 B |
EBITDA (LTM) |
$ 1.34 B |
P/E (LTM) |
11.97 |
P/S (LTM) |
6.14 |
EPS (LTM) |
66.36 |
Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.
Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.
One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.
The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
- | -6.08 % | $ 184 M | Nasdaq Global Select Market |  China |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market | China |
 |
Synthetic Biologics
SYN
|
- | 1.32 % | $ 16.2 M | NYSE American | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 1.19 | 5.31 % | $ 14.5 M | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 4.37 | 0.23 % | $ 958 M | NYSE |  Britain |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
BeyondSpring
BYSI
|
$ 0.84 | 34.27 % | $ 34.5 M | Nasdaq Capital Market | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Cerus Corporation
CERS
|
$ 2.98 | 4.93 % | $ 568 M | Nasdaq Global Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.41 | 4.17 % | $ 225 M | Nasdaq Global Market,SPB |  Israel |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market | Britain |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB |  Russia |
|
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
- | -18.79 % | $ 39.3 K | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | Germany |
|
Champions Oncology
CSBR
|
$ 5.1 | 2.63 % | $ 70.5 M | Nasdaq Capital Market | USA |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | China |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.98 | 1.86 % | $ 2.66 M | Nasdaq Capital Market | USA |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
AnaptysBio
ANAB
|
$ 58.47 | 4.37 % | $ 1.68 B | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.5 | 1.56 % | $ 308 M | Nasdaq Global Select Market,SPB | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | China |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 15.47 | 1.91 % | $ 2.08 B | Nasdaq Global Market | Canada |
 |
GlycoMimetics
GLYC
|
- | 9357.83 % | $ 1.01 B | Nasdaq Global Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.9 | 0.24 % | $ 270 M | Nasdaq Global Select Market | Britain |
 |
Beam Therapeutics
BEAM
|
$ 26.75 | 0.91 % | $ 2.65 B | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 67.36 | 0.99 % | $ 12.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.